6月1日 演題レポート
Abstract #3500
Effect of 3-5 Years of Scheduled CEA and CT Follow-up to Detect Recurrence of Colorectal Cancer: FACS Randomized Controlled Trial.
David Mant, et al.
Abstract #3501
Phase III Randomized, Placebo (PL)-controlled, Double-blind Study of Intravenous Calcium/Magnesium (CaMg) to Prevent Oxaliplatin-induced Sensory Neurotoxicity (sNT), N08CB: An Alliance for Clinical Trials in Oncology Study.
Charles L. Loprinzi, et al.
Abstract #3502
Maintenance Treatment with Capecitabine and Bevacizumab versus Observation after Induction Treatment with Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer (mCRC) : The Phase III CAIRO3 Study of the Dutch Colorectal Cancer Group (DCCG).
Miriam Koopman, et al.
Abstract #3503
Bevacizumab Continuation versus No Continuation after first-line Chemo-Bevacizumab Therapy in Patients with Metastatic Colorectal Cancer: a Randomized Phase III non-Inferiority Trial.
Dieter Koeberle, et al.
Abstract #3504
A Randomised Clinical Trial of Chemotherapy Compared to Chemotherapy in Combination with Cetuximab in KRAS wild-type Patients with Operable Metastases from Colorectal Cancer: The New EPOC study
John Primrose, et al.
Abstract #3505
FOLFOXIRI/Bevacizumab (Bev) versus FOLFIRI/Bev as 1st-line Treatment in Unresectable Metastatic Colorectal Cancer (mCRC) Patients (pts): Results of the Phase III TRIBE Trial by GONO group.
Alfredo Falcone, et al.
Abstract #LBA3506
Randomized Comparison of FOLFIRI Plus Cetuximab versus FOLFIRI Plus Bevacizumab as 1st-line Treatment of KRAS Wild-type Metastatic Colorectal Cancer: German AIO Study KRK-0306 (FIRE-3).
Volker Heinemann, et al.
Abstract #3507
Pharmacodynamic and Efficacy Analysis of the BRAF Inhibitor Dabrafenib (GSK436) in Combination with the MEK Inhibitor Trametinib (GSK212) in Patients with BRAF V600 Mutant Colorectal Cancer (CRC)
Ryan B. Corcoran, et al.
Abstract #3508
A Randomized, Placebo-Controlled, Phase 2 Study of Tivantinib (ARQ 197) in Combination With Cetuximab and Irinotecan as Second-line Therapy in Patients With KRAS Wild?Type Metastatic Colorectal Cancer (CRC).
Cathy Eng, et al.